HAMP and breast carcinoma: Based on this value, breast cancer patients were divided into two groups according to hepcidin levels; Group 1: Low hepcidin (Hepcidin ≤ 26.6 ng/mL) comprising 19 patients, and Group 2: High hepcidin (Hepcidin > 26.6 ng/mL) comprising 20 patients (Table 5).